Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anhui Heryi Pharmaceutical CoBJSE:920478 77 EBITDA Margin % is 4.02% as of Mar. 2026, which is 86% below its 10-year median of 28.28. GuruFocus rates BJSE:920478 with a GF Score™ of 77/100 and a GF Value™ of ¥10.49 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 958 Drug Manufacturers companies, Anhui Heryi Pharmaceutical Co ranks better than 55.32% on this metric.
Anhui Heryi Pharmaceutical Co (BJSE:920478) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Anhui Heryi Pharmaceutical Co EBITDA Margin % Related Terms
Anhui Heryi Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anhui Heryi Pharmaceutical Co EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Anhui Heryi Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anhui Heryi Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anhui Heryi Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Anhui Heryi Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anhui Heryi Pharmaceutical Co (BJSE:920478) has a EBITDA Margin % of 4.02% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anhui Heryi Pharmaceutical Co and its competitors. This is 86% below median its historical median of 28.28. Over the past decade, Anhui Heryi Pharmaceutical Co's EBITDA Margin % has ranged from 14.06 to 56.65. According to the industry distribution chart, Anhui Heryi Pharmaceutical Co ranks #428 out of 958 companies in the Drug Manufacturers industry, placing it in the top 44.7%.
Is Anhui Heryi Pharmaceutical Co's EBITDA Margin % too high?
Anhui Heryi Pharmaceutical Co's current EBITDA Margin % of 4.02% is 86% below median its 10-year median of 28.28. Over the past 10 years, this metric has ranged from a low of 14.06 to a high of 56.65. The Drug Manufacturers industry median EBITDA Margin % is 11.93. Anhui Heryi Pharmaceutical Co's value of 4.02% is 66.3% below this industry median. Based on the distribution chart, Anhui Heryi Pharmaceutical Co ranks #428 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Anhui Heryi Pharmaceutical Co has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Anhui Heryi Pharmaceutical Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Anhui Heryi Pharmaceutical Co ranks #428 out of 958 companies for EBITDA Margin %. This puts Anhui Heryi Pharmaceutical Co in the upper half of its industry. The industry median EBITDA Margin % is 11.93. Anhui Heryi Pharmaceutical Co's value of 4.02% is 66.3% below this benchmark. Historically, Anhui Heryi Pharmaceutical Co's own EBITDA Margin % has ranged from 14.06 to 56.65 over the past decade. While the company's 10-year median is 28.28 vs. the industry median of 11.93, Anhui Heryi Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.93, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anhui Heryi Pharmaceutical Co's current EBITDA Margin % of 4.02% is 66.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anhui Heryi Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anhui Heryi Pharmaceutical Co's current EBITDA Margin % is 4.02%, which is 86% below median its own 10-year median of 28.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anhui Heryi Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Anhui Heryi Pharmaceutical Co (BJSE:920478) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥10.49, compared to a current price of ¥12.30 — trading 17.3% above its estimated fair value. The current EBITDA Margin % is 4.02%, which is 86% below median its 10-year median of 28.28 and 66.3% below the Drug Manufacturers industry median of 11.93. Anhui Heryi Pharmaceutical Co's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Anhui Heryi Pharmaceutical Co (BJSE:920478), the current EBITDA Margin % is 4.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anhui Heryi Pharmaceutical Co (BJSE:920478) Overvalued in 2026?
Based on GuruFocus' analysis, Anhui Heryi Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥12.30 is trading 17.3% above its estimated GF Value™ of ¥10.49.
GuruFocus considers Anhui Heryi Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for BJSE:920478:
EBITDA Margin %: 4.02% (86% below median its 10-year median of 28.28)
GF Value™: ¥10.49 vs. price of ¥12.30 (17.3% above fair value)
Industry Position: 66.3% below the Drug Manufacturers median (#428 of 958)
No single metric tells the full story. See the BJSE:920478 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anhui Heryi Pharmaceutical Co Ltd engages in research and development, production, and sales of pharmaceutical intermediates, raw materials, and related products. The main product categories include anti-allergy, anti-thrombosis, anti-oxidation, gastric ulcer, anti-virus, antipyretic and analgesic, and ultraviolet absorbent.
77GF Score
Get the complete analysis for BJSE:920478
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920478 has been successfully added to your 
